ClinicalTrials.gg
TerminatedNCT03376477Updated Aug 27, 2025Results posted

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

A Phase 2 interventional study of GM-CSF vaccine and Lenalidomide in Multiple Myeloma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

Why this study was terminated
loss of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Multiple Myeloma by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — 1 open to participants now, 2 under way, none of them phase 3. Multiple Myeloma · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Enrollment
15th of 24
24 · median 29
Started
2019
the only one that year
Phase 2
14 of 29
none open now
Registered
27th of 29
by date

Among the 29 studies in Multiple Myeloma by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, this one is the 15th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2019, is one of 14 in phase 2, and was the 27th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 29 studies in Multiple Myeloma by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Multiple Myeloma by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, or all of them as a file.
02

Study summary

This study seeks to determine whether addition of an allogeneic myeloma vaccine can augment clinical responses to lenalidomide in patients with near complete remission (nCR), or complete remission (CR) leading to a significant improvement in progression-free survival.This main objective of this study is to compare the 2-year progression free survival of patients with multiple myeloma in CR or nCR, treated with lenalidomide plus an allogeneic myeloma vaccine in combination with lenalidomide (with or without Prevnar vaccine) or versus placebo in combination with lenalidomide (control arm).

Read the detailed description

This is a single institution, three- arm, randomized controlled, Phase II study examining the clinical efficacy of an allogeneic GM-CSF secreting myeloma vaccine in combination with lenalidomide (with or without Prevnar) compared to lenalidomide and placebo (control arm).

Patients enrolled in the study must have two disease measurements (including the last one) consistent with a near complete remission (M-spike negative with persistence of immunofixation), or complete remission (M-spike negative, negative immunofixation, and \<5% clonal plasma cells on bone marrow) per criteria for response in a 3 month period. All patients must be minimal residual disease (MRD) positive by NGS sequencing at enrollment.

Prior to enrollment, patients will have been treated with a lenalidomide containing regimen for a minimum of 6 cycles. All patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.

Patients will be randomized to receive either an allogeneic myeloma vaccine and Prevnar vaccine in combination with lenalidomide, or allogeneic myeloma vaccine without Prevnar vaccine in combination with lenalidomide, or lenalidomide in combination with placebo. Patients will receive allogeneic myeloma vaccine or placebo injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter for up to 3 years. If assigned to allogeneic myeloma vaccine plus Prevnar vaccine arm, Prevnar-13 will be administered with each allogeneic myeloma vaccine. If assigned to either of the two arms that do not include Prevnar, then patients will receive a placebo in lieu of Prevnar on the same schedule. All patients will be followed for a minimum of 3 years.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Lenalidomide
  • M-spike negative
  • GVax
  • GM-CSF secreting myeloma vaccine
  • MRD positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Myeloma eligibility criteria are the following:
  • Near complete remission (nCR) for ≥ 3 months defined as no measurable M-spike, and a positive serum immunofixation

    • For patients with a light chain only myeloma, they will be in deemed to be in a CR if they meet criteria for CR by International Myeloma Working Group (IMWG) consensus criteria 2016.
    • For patients with a light chain only myeloma that meet criteria for Very Good Partial Response (VGPR) by IMWG consensus criteria 2016 and are IFE -ve (negative serum immunofixation), they will be considered to be in a near complete remission (nCR).
  • Or complete remission (CR) (no measurable M-spike, immunofixation negative and bone marrow plasma cells \<5%)
  • NDMM or RMM in nCR or CR having completed a minimum of 6 cycles of a lenalidomide based regimen for a minimum of ≥ 3 months
  • NDMM or RMM a patients who have been off for ≥ 4 weeks
  • Patients with NDMM or RMM who have had stem cell transplant are eligible, but must be ≥ 12 months from transplant
  • All patients must be MRD positive at 10-4 or greater by NGS sequencing at enrollment
  • All patients must be currently taking Revlimid at screening.
  • Age >18 years
  • performance scores 0-2
  • History of measurable serum or urine M protein or free light chains
  • greater than 12 months
  • Corrected serum calcium \< 11 mg/dL, and no evidence of symptomatic hypercalcemia
  • Serum creatinine\< 2 mg/dl
  • >1000/µL
  • >100,000/µL
  • Total \<= 1.5 x
  • (SGOT) and ALT (SGPT) \<= 3 x ULN.
  • Ability to comprehend and have signed the .
  • Have previously agreed to continue on maintenance therapy with lenalidomide concurrent with vaccine administration until disease progression, or clinical indication to cease therapy.
  • Disease free of prior for at least 5 years with exception of currently treated basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the uterus, cervix or breast.
  • All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program.
  • Females of must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.
  • Females of (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to starting lenalidomide with each cycle (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of , one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
  • Able to take prophylactic anticoagulation (aspirin 81 or 325 mg/daily or, for patients intolerant to ASA, warfarin or low molecular weight heparin).

Exclusion criteria

Exclusion Criteria:

  • Disease progression after stopping as defined as the appearance of a detectable serum or urine M-spike, or an absolute increase of >10 mg/dl between involved and uninvolved light chains, in the absence of measurable serum or urine M-protein .
  • Patients who are MRD negative by NGS at screening.
  • Patients with a known diagnosis of POEMS syndrome, plasma cell leukemia, CNS involvement, non-secretory myeloma and amyloidosis
  • High-risk myeloma defined by presence of at least one of the following defining features on initial diagnostic, or most recent bone marrow :
  • High risk chromosomal translocations by FISH: t(4;14), t(14;16), t(14;20),
  • del(17p), del(1p), amplification 1q.;
  • MyPRS GEP-70 high risk signature either from diagnosis or at time of registration for the study;
  • LDH > 300 U/L at diagnosis;
  • Relapse from prior therapy within 12 months.
  • disease, active infection requiring treatment with antibiotics, anti-fungal or anti-viral agents within 2 weeks of enrollment would be excluded from the study.
  • Patients who have participated in any clinical trial, within the last four weeks, which involved an drug.
  • History of an active other than myeloma
  • disease requiring active treatment.
  • Known to any component of allogeneic myeloma vaccine
  • History of an transplant
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Lenalidomide plus GM-CSF Vaccine plus Prevnar13

    Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Prevnar vaccine will be administered with the GM-CSF vaccine administration.

    Biological: GM-CSF vaccine · Drug: Lenalidomide · Drug: Prevnar13

  • Placebo comparator
    Lenalidomide Only

    Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients will also get placebo GM-CSF vaccine and placebo prevnar13. Placebo will be saline.

    Drug: Lenalidomide · Other: Placebo Prevnar13 · Other: Placebo GM-CSF Vaccine

  • Placebo comparator
    Lenalidomide plus GM-CSF Vaccine

    Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Patients will also be administered a placebo prevnar13 vaccination. Placebo will be saline.

    Biological: GM-CSF vaccine · Drug: Lenalidomide · Other: Placebo Prevnar13

Interventions

  • BiologicalGM-CSF vaccine

    Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.

    Also known as: GVAX

  • Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).

    Also known as: Revlimid

  • Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.

    Also known as: pneumococcal vaccine

  • OtherPlacebo Prevnar13

    Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.

  • OtherPlacebo GM-CSF Vaccine

    Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.

06

What researchers measure

Primary outcomes

  1. 2-year Progression Free Survival

    Number of participants without disease progression at 2 years.

    Time frame: 2 years

Secondary outcomes

  1. Response Conversion Rate

    Number of participants who converted from near complete remission (nCR) to complete remission (CR) as measured by the International Myeloma Working Group Uniform Response Criteria. Near complete remission is defined as negative serum and urine electrophoresis, \< 5% plasma cells in the bone marrow, and positive serum and/or urine immunofixation. Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells.

    Time frame: 2 years

  2. MRD Conversion Rate

    Number of participants who convert from MRD (Minimal Residual Disease) positive status to MRD negative status as determined through next generation sequencing (NGS).

    Time frame: 2 years

  3. Time to Response

    Median time for conversion of response from near complete remission (nCR) to complete remission (CR) as measured by the International Myeloma Working Group Uniform Response Criteria. Near complete remission is defined as negative serum and urine electrophoresis, \< 5% plasma cells in the bone marrow, and positive serum and/or urine immunofixation. Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells as measured by immunofixation converting from positive to negative.

    Time frame: 2 Years

  4. Progression Free Survival (PFS)

    Number of months without disease progression.

    Time frame: 3 and 5 years

  5. Evaluate Toxicity of Allogenic Myeloma Vaccine

    Number of participants experiencing adverse events grade 3 or higher, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)

    Time frame: 3 years

  6. Measure Tumor Specific Immunity and Correlate With Systemic Immunity

    Time frame: 3 years

07

Results

Posted Aug 27, 2025
Limitations and caveats
Recruitment was significantly negatively impacted by COVID pandemic

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide Plus GM-CSF Vaccine (Arm A)Lenalidomide Plus GM-CSF Vaccine Plus Prevnar13 (Arm B)Lenalidomide Only (Arm C)
Started341
Completed331
Not completed010

Outcome measures

Primary2-year Progression Free Survival

Number of participants without disease progression at 2 years.

Time frame:
2 years
Reported as:
Count of participants · Participants
2-year Progression Free Survival
ParticipantsLenalidomide Plus GM-CSF Vaccine Plus Prevnar13 (Arm A)Lenalidomide Plus GM-CSF Vaccine (Arm B)Lenalidomide Only (Arm C)
2-year Progression Free Survival331
SecondaryResponse Conversion Rate

Number of participants who converted from near complete remission (nCR) to complete remission (CR) as measured by the International Myeloma Working Group Uniform Response Criteria. Near complete remission is defined as negative serum and urine electrophoresis, \< 5% plasma cells in the bone marrow, and positive serum and/or urine immunofixation. Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells.

Time frame:
2 years
Reported as:
Count of participants · Participants
Response Conversion Rate
ParticipantsLenalidomide Plus GM-CSF Vaccine (Arm A)Lenalidomide Plus GM-CSF Vaccine Plus Prevnar13 (Arm B)Lenalidomide Only (Arm C)
Response Conversion Rate000
SecondaryMRD Conversion Rate

Number of participants who convert from MRD (Minimal Residual Disease) positive status to MRD negative status as determined through next generation sequencing (NGS).

Time frame:
2 years
Reported as:
Count of participants · Participants
MRD Conversion Rate
ParticipantsLenalidomide Plus GM-CSF Vaccine (Arm A)Lenalidomide Plus GM-CSF Vaccine Plus Prevnar13 (Arm B)Lenalidomide Only (Arm C)
MRD Conversion Rate000
SecondaryTime to Response

Median time for conversion of response from near complete remission (nCR) to complete remission (CR) as measured by the International Myeloma Working Group Uniform Response Criteria. Near complete remission is defined as negative serum and urine electrophoresis, \< 5% plasma cells in the bone marrow, and positive serum and/or urine immunofixation. Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells as measured by immunofixation converting from positive to negative.

Time frame:
2 Years
Reported as:
Median · days
Time to Response
daysLenalidomide Plus GM-CSF Vaccine (Arm A)Lenalidomide Plus GM-CSF Vaccine Plus Prevnar13 (Arm B)Lenalidomide Only (Arm C)
Time to ResponseNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryProgression Free Survival (PFS)

Number of months without disease progression.

Time frame:
3 and 5 years

No measurements were reported for this outcome.

SecondaryEvaluate Toxicity of Allogenic Myeloma Vaccine

Number of participants experiencing adverse events grade 3 or higher, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)

Time frame:
3 years

No measurements were reported for this outcome.

SecondaryMeasure Tumor Specific Immunity and Correlate With Systemic Immunity
Time frame:
3 years

No measurements were reported for this outcome.

Adverse events

Collected over From enrollment up to 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide Plus GM-CSF Vaccine Plus Prevnar13 (Arm A)0/3 (0%)0/3 (0%)1/3 (33.3%)
Lenalidomide Only (Arm C)0/4 (0%)0/4 (0%)0/4 (0%)
Lenalidomide Plus GM-CSF Vaccine (Arm B)0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventLenalidomide Plus GM-CSF Vaccine Plus Prevnar13 (Arm A)Lenalidomide Only (Arm C)Lenalidomide Plus GM-CSF Vaccine (Arm B)
Basal cell, noseNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/41/1
FallInjury, poisoning and procedural complications1/30/40/1

Baseline characteristics

Data was collected for 8 participants

Age, Categorical
Age, Categorical(Participants)ARM A - Lenalidomide + GM-CSF Vaccine + Placebo Prevnar13ARM B - Lenalidomide + GM-CSF Vaccine + Prevnar13ARM C - Lenalidomide Only + Placebo GM-CSF Vaccine + Placebo Prevnar13Total
<=18 years0000
Between 18 and 65 years1203
>=65 years2215
Sex: Female, Male
Sex: Female, Male(Participants)ARM A - Lenalidomide + GM-CSF Vaccine + Placebo Prevnar13ARM B - Lenalidomide + GM-CSF Vaccine + Prevnar13ARM C - Lenalidomide Only + Placebo GM-CSF Vaccine + Placebo Prevnar13Total
Female1102
Male2316
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ARM A - Lenalidomide + GM-CSF Vaccine + Placebo Prevnar13ARM B - Lenalidomide + GM-CSF Vaccine + Prevnar13ARM C - Lenalidomide Only + Placebo GM-CSF Vaccine + Placebo Prevnar13Total
Hispanic or Latino0000
Not Hispanic or Latino3418
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARM A - Lenalidomide + GM-CSF Vaccine + Placebo Prevnar13ARM B - Lenalidomide + GM-CSF Vaccine + Prevnar13ARM C - Lenalidomide Only + Placebo GM-CSF Vaccine + Placebo Prevnar13Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0202
White3216
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21287, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Jan 2024, 51 months.

Results were first posted in Aug 2025, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Dec 18, 2017
StartActual
Sep 23, 2019
Primary completionActual
Jan 2, 2024
CompletionActual
May 30, 2025
Results first posted
Aug 27, 2025
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03376477
Collaborators
Celgene, Aduro Biotech, Inc.
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Sep 23, 2019
Primary completion
Jan 2, 2024
Completion
May 30, 2025
Results posted
Aug 27, 2025
Last update
Aug 27, 2025

Study contacts

Syed A Ali, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion